Volume 130, Issue 3, Pages (September 2013)

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Port-site recurrence in a patient undergoing robotic hysterectomy and lymph node dissection for endometrioid adenocarcinoma of the uterus Ioannis Alagkiozidis,
Volume 144, Issue 1, Pages (January 2017)
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
A Strategy to Find Suitable Reference Genes for miRNA Quantitative PCR Analysis and Its Application to Cervical Specimens  Iris Babion, Barbara C. Snoek,
Volume 148, Issue 1, Pages (January 2018)
Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow 
Are patients willing to travel for better ovarian cancer care?
L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L
Volume 146, Issue 3, Pages (September 2017)
A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L
Volume 151, Issue 1, Pages (October 2018)
Eun-Jung Jung, George A. Calin  Cancer Cell 
Volume 145, Issue 2, Pages (May 2017)
Volume 138, Issue 1, Pages (July 2015)
Vulvar intraepithelial neoplasia: Risk factors for recurrence
Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs  McDermott Niamh , Meunier Armelle , Wong Simon , Buchete.
Volume 145, Issue 3, Pages (June 2017)
Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008]  Douglas.
Volume 144, Issue 2, Pages (February 2017)
M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns
MicroRNAs and Parallel Stem Cell Lives
RNA sequencing (RNA-Seq) and its application in ovarian cancer
Volume 152, Issue 1, Pages (January 2019)
Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei 
Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum  E.E. Stevens, J.N. Bottsford-Miller,
Volume 142, Issue 3, Pages (September 2016)
National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence  J. Chino, J.R. Foote,
Volume 152, Issue 1, Pages (January 2019)
Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer  E.N. Prendergast,
Volume 151, Issue 1, Pages (October 2018)
K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani
Volume 147, Issue 2, Pages (November 2017)
Volume 152, Issue 1, Pages (January 2019)
Volume 143, Issue 2, Pages (November 2016)
Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base  A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,
The origins of multidisciplinary cancer care
Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)
Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM)  C. Popadiuk, A.J. Coldman,
I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M
Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum  A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,
Volume 130, Issue 6, (September 2007)
Volume 152, Issue 1, Pages (January 2019)
Volume 150, Issue 1, Pages (July 2018)
Volume 152, Issue 1, Pages (January 2019)
Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates  N.A. Latif, E.M. Ko,
Volume 130, Issue 1, Pages (July 2013)
Volume 152, Issue 1, Pages (January 2019)
Volume 147, Issue 1, Pages (October 2017)
Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.
Volume 130, Issue 3, Pages (September 2013)
Validation study of endogenous reference genes for normalization of quantitative real time PCR data in post mortem skin tissue  I. Gomes, K. Becker, M.A.
The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough  K.M. Doll, E.L. Barber, J.T. Bensen,
Volume 142, Issue 2, Pages (August 2016)
Annika Idahl, Andrea Hermansson, Ann Lalos  Gynecologic Oncology 
Volume 150, Issue 3, Pages (September 2018)
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer  M. Dandapani, B.L. Seagle, R. Samuelson,
Volume 130, Issue 1, Pages (July 2013)
Volume 142, Issue 3, Pages (September 2016)
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Volume 147, Issue 3, Pages (December 2017)
High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States  J.R.
IASLC 6th Latin American Conference on Lung Cancer
Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma?  L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,
Volume 115, Issue 1, Pages (October 2009)
Volume 134, Issue 6, (September 2008)
Volume 154, Issue 2, Pages (August 2019)
Presentation transcript:

Volume 130, Issue 3, Pages 588-594 (September 2013) Selection and validation of endogenous controls for microRNA expression studies in endometrioid endometrial cancer tissues  Anna Torres, Kamil Torres, Paulina Wdowiak, Tomasz Paszkowski, Ryszard Maciejewski  Gynecologic Oncology  Volume 130, Issue 3, Pages 588-594 (September 2013) DOI: 10.1016/j.ygyno.2013.06.026 Copyright © 2013 The Authors Terms and Conditions

Fig. 1 NormFinder analyses performed without taking groups into account; (a) panel of 12 candidate genes (in the group of 32 samples); (b) panel of 9 candidate genes (in the group of 45 samples). Gynecologic Oncology 2013 130, 588-594DOI: (10.1016/j.ygyno.2013.06.026) Copyright © 2013 The Authors Terms and Conditions

Fig. 2 NormFinder analyses performed without taking groups into account after excluding miR-92a, miR-26b and U18A; (a) panel of 9 candidate genes (in the group of 32 samples); (b) panel of 7 candidate genes (in the group of 45 samples); (c) accumulated SD obtained in NormFinder analysis after excluding miR-92a, miR-26b and U18A (in the group of 45 samples). Gynecologic Oncology 2013 130, 588-594DOI: (10.1016/j.ygyno.2013.06.026) Copyright © 2013 The Authors Terms and Conditions

Fig. 3 geNorm analyses; (a) analysis performed in the panel of 12 candidate genes (in the group of 32 samples); (b) analysis performed in the panel of 9 candidate genes (in the group of 45 samples); (c) determination of the optimal number of ECs for normalization. Gynecologic Oncology 2013 130, 588-594DOI: (10.1016/j.ygyno.2013.06.026) Copyright © 2013 The Authors Terms and Conditions